Protagenic Therapeutics

Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pieris Pharma

Sesen Bio Inc.

T2 Biosystems

Looking for biotech penny stocks for your June watchlist? Here's 4 to watch The post Best Biotech Penny Stocks in June 2021?

Best Biotech Penny Stocks in June 2021? Check These 4 Out

iBio

Obalon Therapeutics

Precipio

These biotech penny stocks pushed up big today; but are they worth it? The post 4 Biotech Penny Stocks That You Need to Know About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Biotech Penny Stocks That You Need to Know About

Cellect Biotechnology Ltd

CKX Lands

Cue Biopharma

Eltek

SemiLEDs

PolarityTE Inc

Regional Health Properties

Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day. The post Market Update: The 10 Most Volatile Stocks Today appeared first on InvestorPlace.

Market Update: The 10 Most Volatile Stocks Today

The stock price of Protagenic Therapeutics Inc (NASDAQ: PTIX) increased by over 80% during intraday trading. This is why it happened.

PTIX Stock: Over 80% Increase Intraday Explanation

New York, April 29, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the closing of an underwritten public offering of 3,180,000 units at a public offering price of $4.15 per unit. Each unit is comprised of one share of common stock and one warrant to purchase one share of common stock. Each warrant is exercisable at a price of $4.98 per share and will expire five years from issuance. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 477,000 units at the public offering price less the underwriting discounts and commissions. The common stock and warrants comprising the units separated upon closing of the offering and were issued separately.

Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq

New York, April 26, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the pricing of an underwritten public offering of 3,180,000 units at a public offering price of $4.15 per unit for aggregate gross proceeds of approximately $13.2 million prior to deducting underwriting discounts, commissions, and other offering expenses. Each unit is comprised of one share of common stock and one warrant to purchase one share of common stock. Each warrant is exercisable for one share of common stock at an exercise price of $4.98 per share and will expire five years from issuance. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 477,000 units at the public offering price less the underwriting discounts and commissions. The offering is expected to close on or around April 29, 2021, subject to satisfaction of customary closing conditions.

Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering

News for Protagenic Therapeutics Stock (PTIX)